Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26630387 | 0.81 | MAPT (0.43) | KAT2BMAPTPOLBIDO1KMT2A | |
| SCHEMBL26630286 | 0.78 | MAPT (0.43) | KAT2BMAPTPOLBIDO1KMT2A | |
| SCHEMBL26630291 | 0.76 | MEN1 (0.51) | MAPTPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL26630401 | 0.76 | KAT2B (0.40) | KAT2BMAPTPOLBIDO1KMT2A | |
| SCHEMBL4055406 | 0.74 | MEN1 (0.47) | MAPTPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL1593358 | 0.74 | KMT2A (0.44) | KAT2BMAPTPOLBKMT2AMEN1 | |
| SCHEMBL29730504 | 0.74 | ALDH1A1 (0.44) | MAPTPOLBIDO1KMT2AMEN1 | |
| SCHEMBL30505945 | 0.70 | MAPT (0.43) | KAT2BMAPTPOLBIDO1KMT2A | |
| SCHEMBL26630166 | 0.70 | MAPT (0.43) | KAT2BMAPTPOLBIDO1KMT2A | |
| SCHEMBL1592603 | 0.70 | MAPT (0.37) | KAT2BMAPTPOLBIDO1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282735-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | DONG-A ST CO., LTD. (KR) | 2025-09-11 | — | — | US | disclosed |
| EP-4514780-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | Dong-A ST Co., Ltd. (KR) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023209651-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | DONG-A ST CO., LTD. (KR) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282735-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | TEAD1, TEAD2, TEAD3 | KAT2B 2242/4885MAPT 34/4885POLB 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.